What the 2026 Cholesterol Guidelines Actually Change for Patients
Every five to ten years, the American College of Cardiology and the American Heart Association update their formal guidelines for managing cholesterol. The last big update was in 2018. The new one came out March 13, 2026, replacing it. I’ve been reading through the document over the past two months and watching how it changes my own clinical decisions in real time. What I want to do here is translate the parts that actually affect patients, not the dozens of pages of methodology that matter mainly to other cardiologists.
There are three big shifts. The first changes when we start thinking about your cholesterol. The second changes what tool we use to estimate your risk. The third makes a long-overdue recommendation about a cholesterol particle that most people have never had measured.
Shift one: from “high risk” to “long timeline”
The old framework asked one question: how likely is this patient to have a heart attack or stroke in the next ten years? If your ten-year risk was low, we mostly left you alone. If it was high, we started a statin.
The problem with that framework is biological. Heart disease doesn’t develop in ten-year chunks. It develops over decades. A 35-year-old with an LDL of 140 mg/dL has a low ten-year risk by any calculator we’ve ever built. Her thirty-year risk, by the time she reaches her sixties, is substantial. The old guideline left her on the sidelines because the window we were looking through was too short.
The 2026 guideline replaces that ten-year-only frame with a lifelong-prevention frame. It explicitly recognizes that a 35-year-old with a moderately elevated LDL is on a different long-term trajectory than a 35-year-old with a low LDL, and that the difference accumulates as plaque in her arteries over the next thirty years whether or not we intervene. The clinical recommendation now is to assess cholesterol earlier, treat sooner in the right patients, and stop using “low ten-year risk” as a reason to avoid the conversation entirely. In some cases, treatment can start as early as age 30.
In my practice, this aligns with what I’d already been doing for patients with strong family histories of early heart disease or genetic predispositions like elevated Lp(a). The guideline change makes the same framework available for a wider group of younger patients whose lipid trajectories warrant earlier attention.
Shift two: a new risk calculator called PREVENT
For a decade, the standard tool we used to estimate cardiovascular risk was called the Pooled Cohort Equations. You’d plug in age, sex, race, blood pressure, cholesterol numbers, smoking status, and diabetes, and the calculator would spit out a ten-year heart attack and stroke risk. It worked, but it had problems. It overestimated risk in some populations and underestimated it in others. It didn’t account for kidney function, body mass index, or social factors that we now know matter.
The 2026 guideline introduces a replacement called PREVENT, which stands for “Predicting Risk of Cardiovascular Disease EVENTs.” PREVENT was developed using more recent data from a much larger and more diverse population. It estimates both 10-year and 30-year risk in adults aged 30 through 79. It incorporates kidney function, body mass index, blood sugar control, and the patient’s ZIP code (as a proxy for the social determinants of health that affect outcomes). It does away with race as a variable, which had been a controversial element of the older equations.
For most patients, the PREVENT-estimated risk number will be slightly lower than what the older equations would have suggested at the same age. That sounds reassuring at first, but it’s misleading on its own. The 30-year risk number that PREVENT also reports is often the more important one. A 40-year-old with a 4 percent ten-year risk but a 25 percent thirty-year risk is in a very different position than a 40-year-old with a 4 percent ten-year risk and a 6 percent thirty-year risk. The first person needs an active prevention plan. The second can be reassured.
If your cardiologist or primary care doctor hasn’t run a PREVENT estimate on you yet, it’s worth asking for both numbers next time.
Shift three: universal Lp(a) testing
This is the change with the largest practical impact, in my opinion. The new guideline formally recommends that every adult should have their lipoprotein(a) measured at least once in their lifetime. Until now, Lp(a) testing was optional, often skipped, and almost never reimbursed automatically. Many of my patients had never heard of the test until they sat in my office.
Lp(a) is a cholesterol particle that’s genetically determined. Your level is set at birth and doesn’t change meaningfully with diet, exercise, or standard cholesterol medications. About one in five people has an elevated level. Untreated, elevated Lp(a) substantially raises the risk of early heart attack and aortic valve disease. The clinical question of “what do I do about a high Lp(a)” is still partially open, because the first Lp(a)-specific medications are still in late-stage trials. The question of “should I know my number” has been settled by this guideline: yes, once.
If you’ve never had your Lp(a) tested, the next time you have any blood work done is a good time to ask. The test is straightforward, often covered, and you only need it once. If your number is high, that result will reshape what we do for the next thirty years. If it’s normal, you can confidently set the question aside. I wrote about Lp(a) in more depth here, and I recently covered new pooled NIH data on what specific level of Lp(a) carries the most risk.
What the LDL targets look like in the new guideline
The headline LDL targets in the 2026 document:
For patients without major risk factors and a low long-term cardiovascular risk, the LDL goal is under 100 mg/dL.
For patients at risk (diabetes, elevated PREVENT scores, established cardiovascular disease, kidney disease, family history of early heart attacks, elevated Lp(a)), the goal tightens to under 70 mg/dL.
For patients who’ve already had a heart attack or stroke, or who have other very-high-risk features, many cardiologists (myself included) push for under 55 mg/dL. The guideline doesn’t yet make 55 a universal target, but it acknowledges that the most aggressive treatment is appropriate in this group, and the data continues to point toward “the lower the better” with no apparent floor below which further reductions stop helping.
To get there, the toolkit is broader than it used to be. Statins remain the backbone for most patients. Ezetimibe adds on cheaply and meaningfully. PCSK9 inhibitors like Repatha and Praluent bring LDL down by another 50 to 60 percent on top of a statin. The twice-yearly injectable Leqvio achieves similar reductions with much less treatment burden, and was approved as a first-line option in July 2025 (I wrote about that label change here). For the small group of patients on the leading edge of cholesterol genetics, a one-time gene editor now in Phase 1 trials may eventually become a fourth option.
What this means for you
The clearest patient-facing takeaways from the new guideline:
If you’re over 30 and haven’t had a serious cholesterol conversation in the past few years, you should. The 2026 framework wants us starting earlier rather than waiting for a ten-year-risk number to cross a threshold.
If you have a strong family history of early heart attack (a father or brother before age 55, a mother or sister before age 65), the new framework treats you with more urgency than the old one did. Ask for both the PREVENT calculator output and an Lp(a) measurement.
If you’ve ever been told your cholesterol is “borderline” and that you should “try lifestyle changes for a few months and recheck,” that approach is still reasonable for many patients but no longer the only option. If lifestyle alone isn’t moving the number into the new tighter targets, the threshold for starting medication is lower than it used to be.
If you’ve never had your Lp(a) measured, ask for it. Once in your life.
If you’re already on a statin and meeting the old LDL target, look at the new targets. Some patients who were “well controlled” by 2018 standards have room to push further now.
If statins have given you trouble, the noise around statin intolerance hasn’t gone away, but the alternatives are stronger than ever. I’ve written about the statin/muscle question here, and the toolkit beyond statins is more complete than it has been in a long time.
My take
Big guideline updates can feel academic. This one isn’t. The shift to a lifetime-prevention frame, the new PREVENT calculator, and the universal Lp(a) recommendation will change which patients get treated and how aggressively. The biggest losers from the old guideline were patients in their thirties and forties with elevated cholesterol and low ten-year risk numbers who got reassured into doing nothing. The biggest winners from the new one are the same patients.
If you’re one of those patients, the question to bring to your next visit is the simple one. What’s my 30-year risk on PREVENT, what’s my Lp(a), and with those two numbers in hand, what should we actually be doing now rather than at 60?